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ReviewAcute organophosphate (OP) intoxication is important because of its high morbidity and mortality and occur-
rence ofmuscular paralysis associated by inhibition of acetylcholinesterase (AChE) activity at the neuromuscular
junction. Cholinergic crisis, intermediate syndrome (IMS), and OP-induced delayed neuropathy (OPIDN) are the
evidences that can be observed in OP intoxication. The main cause of morbidity due to OP poisoning is IMS that
occurs 24–96 h after poisoning. Mechanisms underlying the IMS are not fully known. Although the electrophys-
iological aspects of delayed neuropathy are best characterized, the IMS remain very little studied. The aim of this
study was to revisit current knowledge related to OP and the IMS. For this purpose, a systematic reviewwithout
date limitation was performed. A total of 599 relevant articles were found and reviewed. Data were categorized
according to experimental and clinical studies. Occurrences of persistent AChE inhibition, electromyography
changes, muscle cell injury, and oxidative stress are the most important pieces of evidence for involvement of
IMS in OP toxicity.
Delayed AChE inhibition, muscle necrosis, down regulation or desensitization of postsynaptic ACh receptors, failure
of postsynaptic ACh release, and oxidative stress-related myopathy are involved in IMS. Toxicokinetic factors, such
as a high lipid-solubility, duration of AChE inhibition andmetabolite excretion, evolution of alterations on repetitive
nerve stimulation (RNS), type and frequency ofmuscle lesions can estimate the probability of the IMS. Plasma AChE
of less than 200 units is a predictor and the 30 Hz RNS decremental response could be a useful marker for the IMS.
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Organophosphate (OP) poisoning is a major global health problem.
This poisoning produces various forms of acute, subacute, or delayedneu-
rotoxicity that causes life-threatening acute neurological complications
such as seizures, paralysis, neuromuscular and cardiac conduction
762 records identified 
through database 
screening:
Google Scholar      684
PubMed           78
Additional records identified through other sources and 
manual search in references of searched article: 37
545 records exclude: 
Studies with no electrophysiological and IMS 
approach, and papers not published in English. 
599 records after duplicates 
599 records screened and reviewed for eligibility
Finally 58 records reviewed
Fig. 1. Flow diagram of the literature reviewing process.
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havioral and electroencephalographic changes to increase in the vari-
ability of action potential (AP) latencies in skeletal muscles.
Cholinergic crisis, intermediate syndrome (IMS), and OP-induced
delayed neuropathy (OPIDN) can be observed in OP intoxication
(Dettbern et al., 2006). OPIDN, a sensory-motor distal axonopathy is
believed to be a result of inhibition of neuropathy target esterase
(Lotti andMoretto, 2005; Vasconcellos et al., 2002). The IMS following
OP poisoning has been described in themid-1980s by Senanayake and
Karalliedde (1987). Approximately 20% of patients following exposure
to OP pesticides may experience IMS (Karalliedde et al., 2006). The
late onset of respiratory failure associated with IMS is amajor contrib-
utor to the high morbidity, mortality, and cost of OP poisoning treat-
ment. The IMS is clinically characterized by weakness in the cranial
nerves, weakness of respiratory, neck and proximal limb muscles,
and depressed deep tendon reﬂexes. These symptoms appear within
24 to 96 h post OP exposure in two types of paralysis. The type 1 paral-
ysis responds to atropine while type 2 does not. Fasciculation that is
seen in type 1 is not part of IMS. Delayed polyneuropathy develops
within 1 to 3 weeks but duration of the IMS varies from a few days
to several weeks (Van den Neucker et al., 1991).
Clinical and experimental electrophysiological studies in the IMS
show that subclinical electrophysiological abnormalities are common
and progressive. Studies demonstrate a repetitive ﬁring following a
single stimulus, gradual reduction in twitch height or compound
muscle action potential (CMAP) followed by an increase with repeti-
tive stimulation (decrement–increment phenomenon), and contin-
ued reduction in twitch height or CMAP with repetitive simulation
(Jayawardane et al., 2009; Karalliedde et al., 2006).
The aim of this study was to gather all data related to IMS and
electromyographic changes that may occur after OP poisoning to clar-
ify understanding the involved mechanisms.
Methods
Bibliographic databases including PubMed and Google Scholar
were searched between years 1953 to 2011 for the keywords “organ-
ophosphate, organophosphorous, intermediate syndrome, myopathy,
neuropathy, and electromyography”. In the ﬁrst step, 599 articles
were found, after elimination of duplicates or irrelevant papers, 58 pa-
pers were selected and reviewed. Reference lists of published articles
were hand-searched to ensure inclusion of all possible studies (Fig. 1).
Results and discussion
IMS description
This syndrome was described in patients who develop proximal
muscle weakness and cranial nerve lesions after recovery from a cho-
linergic crisis. It is apparent that all patients who develop suchweakness have progressive neuromuscular junction dysfunction
since the time of acute exposure. This phenomenon is thought to be
due to primary motor endplate dysfunction resulting from prolonged
inhibition of AChE. This involves both presynaptic and postsynaptic
failures. Patients who develop weakness of proximal muscles, neck
ﬂexion of MRC (Medical Research Council) score of 3/5 or less are at
risk of late respiratory failure. An incomplete IMS is described with
less severe weakness and initial decrement increment progressing
to severe decrement in RNS but not progressing to respiratory failure
(Jayawardane et al., 2008). Clinical weakness of IMS is experienced in
65.55% of patient as reported by Avasthi and Singh (2000), 20% by
Poojara et al. (2003), 42% by De Bleecker et al. (1993), and 49% by
Wadia et al. (1987), with no clear association between the particular
OP pesticide involved and the development of the syndrome. IMS oc-
curring after poisoning by fenthion, monocrotophos, dimethoate,
methylparathion, phosmet, chlorpyrifos, phenthoate, dichlorvos and
methamidophos (De Bleecker et al., 1992, 1993; De Wilde et al.,
1991; Good et al., 1993; Jayawardane et al., 2008; Jin et al., 2008;
Karademir et al., 1990; Senanayake and Karalliedde, 1987; Van den
Neucker et al., 1991; Van den Neucker et al., 1991).
Respiratory failure caused by IMS
The respiratory failure is mostly a consequence of nicotinic paral-
ysis of the respiratory muscles. The diaphragm is involved out of
proportion to other muscles in IMS. Studies of acute OP poisoning
in experimental animals have revealed that muscle necrosis is
much more severe in the diaphragm in comparison to other skeletal
muscles (Ariens et al., 1969; Wadia et al., 1974). However, the respi-
ratory failure may occur in acute OP intoxication because of musca-
rinic hyperactivity that can lead to excessive airway secretions and
a central respiratory depression. Also, respiratory failure as a compli-
cation of endotracheal intubation can be caused by arytenoid dislo-
cation or subluxation, or compression injury (Jin et al., 2008).
Phrenic nerve conduction study in one patient with impending re-
spiratory failure revealed an unstimulable phrenic nerve (Singh
et al., 1998). Isolated bilateral vocal cord paralysis that recorded by
laryngeal electromyography should be excluded as a cause, if dys-
phonia or respiratory distress occurs after extubation in patients
with IMS (Jin et al., 2008).
Electrophysiological changes during IMS
The electrophysiological aspects of delayed neuropathy are best
characterized, but those of crisis and IMS remain very little studied.
There are several electrodiagnostic testing in the better manage-
ment of patients with OP poisoning. RNS studies can help in under-
standing the abnormalities observed during the progression and
development of IMS. Single ﬁber electromyography (SFEMG) is an-
other electrodiagnostic technique that allows evaluation of single
Table 1
Electromyographic ﬁndings reported in the clinical and animal studies appeared in close relationships with cases of IMS.
Clinical and animal studies Human/animal Pesticide Electromyographic ﬁnding
Maselli et al. (1986) Human Methyl parathion Repetitive CMAP & ↓response at higher rates of stimulation in SNS
Senanayake and Karalliedde (1987) Human Fenthion
Monocrotophos
Dimethoate
Methamidophos
Fade on tetanic stimulation, absence of fade on low frequency
stimulation, and post-tetanic facilitation, suggestive of a postsynaptic defect
Wadia et al. (1987) Human Diazinon
Malathion
Fenthion
Sumithion
↓CMAP & repetitive CMAP in RNS
Besser-Gutmann et al. (1989) Human Unknown ↓Evoked CMAP, decrement–increment phenomenon in RNS
De Wilde et al. (1991) Human Fenthion Fade on tetanic stimulation, absence of fade on low frequency stimulation,
and post-tetanic facilitation
Maselli and Soliven (1991) Rat DPFP Repetitive CMAPs in response to a single stimulus; ↓response to RNS
Van den Neucker et al. (1991) Human Fenthion Neuromuscular junctional dysfunction
De Bleecker et al. (1992) Human Dimethoate ↓Response at low rates of RNS, ↑at a high rate
De Bleecker et al. (1993) Human Methylparathion
Fenthion Dimethoate
Decrement–increment phenomenon in RNS
Good et al. (1993) Human Phosmet ↓Response at low and high rates of RNS, MEPP, ↓mean ACh sensitivity and
normal MP
De Bleecker et al. (1994) Rat Paraoxon Fenthion Repetitive activity in RNS
↓Amplitude in SNS
Baker and Sedgwick (1996) Human Sarin Small changes in SFEMG with no clinical neuromuscular symptoms
Camara et al. (1997) Rat Methamidophos ↑Amplitude, prolonged the decay phase of nerve-evoked and spontaneous
MEPP
Singh et al. (1998) Human Monocrotophos
Phorate
Repetitive responses & decrement–increment phenomenon in RNS
Dongren et al. (1999) Rat Dimethoate Prolongation of MCD, ↓CMAP
de Blaquiere et al. (2000) Mouse Diazinon
1—Single dose
2—Multiple dose
1—↑Jitter of AP but not EP
2—↑Jitter of EP
Yang et al. (2001) Rat 1—Phoxim
2—Methomyl, fenvalerate
1—↑MCD of SFAP blocking of NMT, jitter abnormalities
2—Jitter abnormalities
Jayawardane et al. (2008) Human Chlorpyrifos
Dimethoate
Phenthoate
Diazinon
Combination of decrement–increment and repetitive fade or severe
decrement at high frequencies
Jin et al. (2008) Human Dichlorvos 1—Widespread ﬁbrillation, positive sharp waves, and ↓AP
Abbreviations: action potentials (AP), compound muscle action potentials (CMAP), diisopropylﬂuorophosphate (DIFP), end-plate potential (EP), mean consecutive difference (MCD),
membrane potentials (MP), miniature end-plate potentials (MEPP), motor nerve conduction velocity (MNCV), repetitive nerve stimulation (RNS), single ﬁber electromyography
(SFEMG), single muscle ﬁber potentials (SFAP), sensory nerve action potentials (SNAP), single nerve stimulation (SNS).
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of the parameters of ﬁber density, jitter (variability of latencies),
and blocking. Fiber density is an indirect estimate of the number
of muscle ﬁbers per unit volume belonging to a single motor unit
(Stalberg and Trontelj, 1979) and is a more sensitive electrophysi-
ological method in the detection of neuromuscular transmission
(NMT) (Baker and Sedgwick, 1996; Dongren et al., 1999; Yang
et al., 2001). Several authors have recorded the clinical and electro-
diagnostic features of the OP-induced nicotinic syndrome (Besser-
Gutmann et al., 1989; Roberts, 1976; Vasconcellos et al., 2002;
Wadia et al., 1974; Wadia et al., 1987) that are summarized in
Table 1. Electrodiagnostic hallmarks of this condition include supra-
maximal electrical stimulus-induced repetitive responses and either
a decremental response, i.e. tetanic fade or a decrement–increment
response at higher frequencies of RNS (Besser-Gutmann et al.,
1989; Jayawardane et al., 2008). A large cohort of OP-poisoned pa-
tients was studied with RNS in the proximal muscle groups that
showed clear progression of electrophysiological changes in parallel
with the development of IMS (Aaron, 2008; Jayawardane et al.,
2008). IMS can be explained by combined pre- and post-synaptic
dysfunctions of NMT (De Bleecker et al., 1993, De Bleecker, 1995;
Senanayake and Karalliedde, 1987). The nature of the NMT failure
that is observed in IMS includes potential mechanisms of pre-
synaptic feedback which may reduce ACh release and post-
synaptic receptor desensitization because of the continual nicotinic
receptor stimulation (Jayawardane et al., 2009; Karalliedde et al.,
2006). Possible causes of muscular fatigue are NMT defects, myop-
athy, and ﬁber type disproportion (Perry et al., 1988). Normalnerve conduction velocities (Jayawardane et al., 2008; Maselli et
al., 1986), distal latency (Wadia et al., 1987), fade on tetanic stim-
ulation (a change in the type of neuromuscular block to a non-
depolarization block) (Baker and Sedgwick, 1996), absence of fade
on low-frequency stimulation, and absence of post-tetanic facilita-
tion (Senanayake and Karalliedde, 1987) suggest that a post-
synaptic defect is the predominant cause of paralytic symptoms.
It was shown that decrement–increment responses at RNS are in-
dicative of a depolarization block due to inactivation of AChE at
the motor end-plate (Singh et al., 1998). Prolonged end-plate po-
tential or repetitive end-plate potentials or a combination of both
can cause a muscle twitch in single nerve stimulation (SNS)
(Clark et al., 1984). A reduction in amplitude of RNS was observed
in weak rats with severe end-plate AChE inhibition (De Bleecker et
al., 1994). Interestingly, sustained end-plate depolarization results
in decrement and weakness in acute OP exposure (Maselli and
Soliven, 1991). Electrophysiological studies have shown that para-
oxon increases neurotransmitter release and causes spontaneous
and impulse-related antidromic nerve activity that induce skeletal
muscle ﬁber necrosis (Wecker et al., 1978).
The possible causes of IMS
Acetylcholinesterase (AChE) inhibition. To produce a muscle ﬁber
contraction, acetylcholine (ACh) is released from the depolarized
motor neuron terminal enters into the synaptic cleft where it binds
to receptors to depolarize the muscle end-plate and muscle ﬁber
sarcolemma. This action results in a calcium-dependent myoﬁber
312 M. Abdollahi, S. Karami-Mohajeri / Toxicology and Applied Pharmacology 258 (2012) 309–314contraction. To allow end-plate repolarization, ACh is rapidly hydro-
lyzed by the enzyme AChE. The acute toxicity of OP is attributable
to the inhibition of AChE and the consequent accumulation of ACh
in the central and peripheral nervous system synapses. The nicotinic
manifestation of OP poisoning is characterized by skeletal muscle in-
volvement in the form of fasciculation and limb and respiratory mus-
cle weakness. Most studies conﬁrm that the pathophysiology of IMS is
not clearly known but the role of persistent excess of ACh at the neu-
romuscular junction cannot be ignored. This persistent severe inhibi-
tion of AChE through the course of poisoning by dimethoate, fenthion,
parathion, and paraoxon underlies the cholinergic crises and IMS (De
Bleecker, 1995; Khan et al., 2001).
In a prospective study in 1993, a delayed and severe AChE inhibi-
tion and relapse of muscarinic symptoms were observed during de-
velopment of IMS in OP-poisoned patients (De Bleecker et al.,
1993). Fenthion and chlorpyrifos were found to produce a gradual in-
crease of cholinergic signs with IMS lasting several days after expo-
sure (De Bleecker, 1995; Lotti et al., 1986). IMS usually occurs
2–4 days after exposure when the symptoms and signs of the acute
cholinergic syndrome are no longer obvious (Karalliedde et al.,
2006). However, failure of AChE to improve the muscle power in
one hand and the similar levels of inhibited AChE between patients
who developed IMS and those who did not on the other hand impli-
cate additional mechanisms in the development of IMS. Of course,
the presence of only nicotinic signs during IMS cannot be explained
by the ‘AChE inhibition theory’ (Aygun et al., 2003; Khan et al.,
2001). AChE inhibition, therefore may initiate other processes
which result in cellular dysfunction. Also reduction of AChE and nico-
tinic ACh receptor mRNA expression occurs after oral poisoning with
disulfoton in rat (Matsuda et al. 2000).
Muscle disorders. The distribution of the weakness in human cases
and experimental animals with IMS can be ascribed to necrosis of
muscle ﬁbers and development of myopathy. However, myopathy
and the IMS have a common origin in ACh accumulation
(Karalliedde et al., 2006) and this has led to speculation that myopa-
thy is involved in induction of IMS. The fall in amplitude of the AP as-
sociated with normal velocity can be explained by a reversible lesion
at the neuromuscular junction and perhaps also at the anterior horn
cell. The anterior horn cell is associated with nicotinic ACh receptors
(Wadia et al., 1987). In this regard, De Bleecker et al. (1994) stated
that myopathy is not aggravated by a further decline in AChE activity
in fenthion poisoning suggesting that the role for persistent AChE in-
hibition as the cause of IMS. Transient weakness is actually muscular
fatigue and other causes such as atrophy or loss of muscle bulk may
be related to IMS.
Severe muscle damage in OP-poisoned patients was shown dur-
ing the cholinergic crises and IMS (Mathew et al., 2002). In exper-
imental animals, acute excess of ACh produces overstimulation of
muscle ﬁbers that leads to muscle degeneration known as acute
myopathy. The severity of the myopathy is positively correlated
with the degree and duration of AChE inhibition (De Bleecker
et al., 1991; Dettbarn, 1984; Wecker et al., 1978). The induction
of skeletal muscle ﬁber necrosis is triggered by inhibition of a neu-
rally regulated fraction of AChE (Wecker et al., 1978). The maximal
necrotizing myopathy in rats occurred within the ﬁrst 24 to 48 h of
the poisoning with paraoxon and mipafox, or fenthion. Also
fenthion caused a limited rhabdomyolysis that correlated with
AChE inhibition (De Wilde et al., 1991). Thirty minutes after single
administration of paraoxon to rats, a dose-dependent necrosis in
skeletal muscle ﬁbers occurred that initiated at the motor end-
plate region and characterized by dilated mitochondria, expanded
sarcoplasmic reticulum, fused and widened subsynaptic folds, and
coated cleft vesicles. By 24 h, a generalized breakdown of muscle
ﬁber architecture was evident with an accompanying inﬁltration
of phagocytes (Wecker et al., 1978). Electron microscopy revealeddegeneration and regeneration of the end-plates in phosmet
human poisoning (Good et al., 1993). In a prospective study, ne-
crotic ﬁbers in muscle biopsies were too sparse to explain severe
muscle weakness (De Bleecker et al., 1993). A single sublethal
dose of sarin in rats induced a non-Wallerian-type axonal degener-
ation of the neuromuscular synapse in the slow twitch, soleus mus-
cle than in the fast extensor digitorum longus muscle. This study
demonstrates a direct cytotoxic effect of sarin in muscles
(Kawabuchi et al., 1991). Muscle is composed of two types of mus-
cle ﬁbers which differ in their enzymatic composition, speed of
contraction, and fatigability. Type I ﬁbers have more oxidative en-
zymes, are less susceptible to fatigue, and are slow twitch ﬁbers.
Type II muscle ﬁbers have a higher proportion of glycolytic en-
zymes and are more-easily fatigued and fast twitch ﬁbers. So we
can conclude that sarin may affect the oxidative cycle in muscles
cells.
Oxidative damage. The events following acute OP poisoning pro-
vide a favorable setting for free radical generation. Free radicals medi-
ate muscle damage and inﬂammation after strenuous exercise as well
as the cellular injury of ischemia reperfusion (Abdollahi et al., 2004;
Soltaninejad and Abdollahi, 2009). Therefore, the extensive muscle
fasciculation and muscle overactivity that occur in the cholinergic cri-
sis of acute OP poisoning and the paralysis which simulates ischemia
reperfusion can both lead to production of free radicals, cellular lipid
peroxidation and muscle damage (Shadnia et al., 2007; Yang and
Dettbarn, 1998). Similar injury on muscle may take place in acute
OP poisoning that contributes to the development of muscle weak-
ness and IMS (Dandapani et al., 2003). One of the sources of free rad-
ical generation in acute OP poisoning is probably muscles
(Amirkabirian et al., 2007). Pretreatment of mice with alpha-
tocopherol and N-acetylcysteine prevented ecothiophate-induced
myopathy that supports the role of oxidative stress in IMS (Kelly
et al., 1992). Also, mechanisms other than ACh-induced oxidative
stress may be involved in the progression of type I to type II paralysis
(Venkatesh et al., 2006).
Other factors. Some OP are metabolized in the liver to much more
active metabolites. These poisons such as parathion, fenthion, chlor-
pyrifos are also usually highly lipid soluble (Davies et al., 1975; de
Blaquiere et al., 2000; De Bleecker et al., 1993) and thus arewidely dis-
tributed into fat. This helps in the occurrence of delayed and pro-
longed ChE inhibitions and consequently occurrence of IMS.
Impairment of systemic functions (cardiovascular, hepatic, and
renal) during OP poisoning that prolongs their metabolisms (De
Bleecker et al., 1993; Jin et al., 2008) can probably lead to IMS. Disrup-
tion of energy metabolism and calcium homeostasis implicates in the
occurrence of IMS (Yang et al., 2002). Another issue is the genetic
polymorphisms in biotransformation of enzymes such as glutathione
S-transferases, cytochromes P450, paraoxonase (Li et al., 2000) or tar-
get molecules that might increase or decrease sensitivity to certain
pesticides and inﬂuence their toxicity (Eaton, 2000). OP-poisoned pa-
tients with genotype of variant allele at 55 codon of PON1, GSTM1 null
and both GSTM1 and GSTT1 null have probably higher risk for IMS
(Xiao et al., 2003). Parathion, phosmet, methylparathion, diazinon,
phoxim, fenthion, and dimethoate with P_S bond are poor AChE in-
hibitors in comparison to methamidophos, dichlorvos, phenthoate,
and monocrotophos with P_O bond. This is because the P_S bond
is less polarized than the P_O bond that results in a phosphorus
atom with low reactivity and minimal capacity to inhibit the enzyme.
This happens mostly through the metabolic oxidation of P_S to P_O
by oxidative desulfuration and causing AChE inhibition (Fukuto,
1990). Although IMS is more likely to occur with some OP, it is not
conﬁned to a few distinct compounds. It seems that IMS relates to
the severity of poisoning not of the speciﬁc OP (Dettbern et al., 2006).
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Fig. 2. A simpliﬁed model outlining potential of mechanisms of neuromuscular junction impairment during IMS caused by OP poisoning.
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Taking collectively, the mechanisms playing the role in induction
and progress of IMS in OP poisoning are summarized and drawn in
Fig. 2. We can conclude that mechanisms of IMS include prolonged
AChE inhibition, muscle necrosis, down regulation or desensitization
of postsynaptic ACh receptors, failure of postsynaptic ACh release,
and oxidative stress-related myopathy. Toxicokinetic factors, such
as a high lipid-solubility, duration of AChE inhibition and metabolite
excretion, evolution of alterations on RNS, type and frequency of
muscle lesions can estimate the probability of the IMS. Due to poten-
tial dangers of IMS, physicians should be aware of the occurrence of
neurotoxic effects and should perform neuromuscular studies to rule
out other causes and predict severity of OP intoxication. Plasma
AChE of less than 200 units is a predictor and the 30 Hz RNS decre-
mental response could be a useful marker for the IMS (Avasthi and
Singh, 2000).
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